Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | PPOX | P50336 | 1/20 | 0.59 |
| ▸ | PYGL | P06737 | 8/20 | 0.43 |
| ▸ | PYGM | P11217 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303379 | 0.88 | TDP1 (0.55) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL30777869 | 0.82 | KMT2A (0.47) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL17530358 | 0.82 | KMT2A (0.47) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11107834 | 0.79 | TDP1 (0.60) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL17542402 | 0.78 | TDP1 (0.44) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10784715 | 0.78 | TDP1 (0.58) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL27343161 | 0.78 | TDP1 (0.65) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL10786867 | 0.77 | TDP1 (0.81) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL9768812 | 0.76 | MEN1 (0.72) | TDP1MEN1KMT2ATTRPPOX | |
| SCHEMBL11147168 | 0.76 | MEN1 (0.72) | TDP1MEN1KMT2ATTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792251-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-3186227-B1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (CH) | 2021-03-24 | — | — | EP | disclosed |
| EP-3792251-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Elanco Tiergesundheit AG (CH) | 2021-03-17 | — | — | EP | disclosed |
| CN-106660961-B | Sulfonylaminobenzamide compounds as anthelmintics | 瑞士伊兰科动物保健有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | ELANCO TIERGESUNDHEIT AG (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | ELANCO TIERGESUNDHEIT AG (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2017-08-10 | — | — | US | disclosed |
| EP-3186227-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033341-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2990403-A1 | ANTHRANILAMIDES, SULFONAMIDES AND NITRO ANALOGUES DERIVED THEREFROM AS ANTHELMINTICS | Novartis Tiergesundheit AG (CH) | 2016-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226053-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | TDP1 4100/4885MEN1 2404/4885KMT2A 663/4885 |
| US-10464889-B2 | Sulfonylaminobenzamide compounds as anthelmintics | PKD2, CATSPER1, ATP1B2 | TDP1 3901/4885MEN1 2215/4885KMT2A 509/4885 |
| US-20180319741-A1 | NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS | PKD2, CATSPER1, PKD1 | TDP1 4100/4885MEN1 2404/4885KMT2A 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.